Business
OpenAI buys Orchestra Bio to bring AI agents that coordinate drug development programs into its Rosalind life sciences suite
OpenAI said on October 20, 2026 that it has acquired Orchestra Bio, a startup whose platform lets biopharma teams hand the monitoring of studies and program timelines to AI agents. Its team and technology will join Rosal…